Últimas noticias sobre Medtronic (NYSE:MDT) Bolsa

Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

BIDU

SOHU

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: MDT, BIDU, SOHU, OXY y FLR.

5 acciones en el foco este martes: MDT, BIDU, SOHU, OXY y FLR

FLNT

PANW

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: LOW, PANW, MDT, FLNT y ALC.

5 acciones en el foco este martes: LOW, PANW, MDT, FLNT y ALC

Medtronic PLC

Measurable Data Token - United States Dollar

MEDIA TECHS INC by Media Technologies Inc.

Media Technologies Inc

MEDIA TEK INC by Media Tek Inc.

MANDATUM OYJ U/ADR by MANDATUM OYJ

MEDITERRANEAN TOWERS LTD by Mediterranean Towers LTD

Mediterranean Towers Ltd

Analysts' ratings for Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Medtronic and provided 12-month price targets. The average target is $95.25, accompanied by a high estimate of $101.00 and a low estimate of $90.00. Observing a downward trend, the current average is 2.81% lower than the prior average price target of $98.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1749211243_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Medtronic among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$98.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$101.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$90.00</td>
<td>$93.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Medtronic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Medtronic's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Medtronic analyst ratings.</a>
<h2>Get to Know Medtronic Better</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
<h3>Financial Insights: Medtronic</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Medtronic's revenue growth over a period of 3M has been noteworthy. As of 30 April, 2025, the company achieved a revenue growth rate of approximately 7.66%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Medtronic's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.84%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Medtronic's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.17% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Medtronic's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.16%, the company showcases efficient use of assets and strong financial health.
Debt Management: Medtronic's debt-to-equity ratio is below the industry average. With a ratio of 0.59, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Medtronic: 4 Analysts Share Their Views

Needham analyst Mike Matson reiterates Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Medtronicto Hold

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/flexible-tracheostomy-tube-recall-medtronic-removes-shiley-adult-flexible-tracheostomy-tube#:~:text=Medtronic%20and%20its%20subsidiary%20Covidien,the%20securement%20flange%20becomes%20disconnected" title="https://www.fda.gov/medical-devices/medical-device-recalls/flexible-tracheostomy-tube-recall-medtronic-removes-shiley-adult-flexible-tracheostomy-tube#:~:text=Medtronic%20and%20its%20subsidiary%20Covidien,the%20securement%20flange%20becomes%20disconnected">https://www.fda.gov/medical-devices/medical-device-recalls/flexible-tracheostomy-tube-recall-medtronic-removes-shiley-adult-flexible-tracheostomy-tube#:~:text=Medtronic%20and%20its%20subsidiary%20Covidien,the%20securement%20flange%20becomes%20disconnected</a>.

Biotech

General

'Flexible Tracheostomy Tube Recall: Medtronic Removes Shiley Adult Flexible Tracheostomy Tube with TaperGuard Cuff Reusable Inner Cannula Due to Risk for Disconnection of the Flange from the Device Cannula' - FDA

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$55.00</td>
<td>$71.1K</td>
<td>2.1K</td>
<td>1.3K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$25.00</td>
<td>$68.0K</td>
<td>2.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$100.00</td>
<td>$44.0K</td>
<td>1.1K</td>
<td>960</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$630.00</td>
<td>$119.6K</td>
<td>6</td>
<td>705</td>
</tr>
<tr>
<td>VEEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$210.00</td>
<td>$65.7K</td>
<td>534</td>
<td>589</td>
</tr>
<tr>
<td>NVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$115.00</td>
<td>$28.0K</td>
<td>1.8K</td>
<td>379</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$80.00</td>
<td>$42.5K</td>
<td>883</td>
<td>372</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$295.00</td>
<td>$40.2K</td>
<td>985</td>
<td>344</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$195.00</td>
<td>$25.8K</td>
<td>5.0K</td>
<td>319</td>
</tr>
<tr>
<td>COR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$280.00</td>
<td>$36.4K</td>
<td>762</td>
<td>200</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a put option sweep that happens to be bearish, expiring in 51 day(s) on July 18, 2025. This event was a transfer of 89 contract(s) at a $55.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $71.1K, with a price of $799.0 per contract. There were 2196 open contracts at this strike prior to today, and today 1320 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 9 day(s) on June 6, 2025. This event was a transfer of 1000 contract(s) at a $25.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $68.0K, with a price of $68.0 per contract. There were 2289 open contracts at this strike prior to today, and today 1083 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a put option trade that happens to be bearish, expiring in 9 day(s) on June 6, 2025. This event was a transfer of 958 contract(s) at a $100.00 strike. The total cost received by the writing party (or parties) was $44.0K, with a price of $46.0 per contract. There were 1139 open contracts at this strike prior to today, and today 960 contract(s) were bought and sold. 
• Regarding REGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), we observe a call option trade with neutral sentiment. It expires in 51 day(s) on July 18, 2025. Parties traded 46 contract(s) at a $630.00 strike. The total cost received by the writing party (or parties) was $119.6K, with a price of $2600.0 per contract. There were 6 open contracts at this strike prior to today, and today 705 contract(s) were bought and sold. 
• Regarding VEEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), we observe a put option sweep with bearish sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 212 contract(s) at a $210.00 strike. This particular put needed to be split into 45 different trades to become filled. The total cost received by the writing party (or parties) was $65.7K, with a price of $310.0 per contract. There were 534 open contracts at this strike prior to today, and today 589 contract(s) were bought and sold. 
• For NVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), we notice a call option sweep that happens to be bullish, expiring in 23 day(s) on June 20, 2025. This event was a transfer of 224 contract(s) at a $115.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $125.0 per contract. There were 1879 open contracts at this strike prior to today, and today 379 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a call option trade that happens to be bearish, expiring in 79 day(s) on August 15, 2025. This event was a transfer of 100 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $42.5K, with a price of $425.0 per contract. There were 883 open contracts at this strike prior to today, and today 372 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option trade with bullish sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 134 contract(s) at a $295.00 strike. The total cost received by the writing party (or parties) was $40.2K, with a price of $300.0 per contract. There were 985 open contracts at this strike prior to today, and today 344 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be bullish, expiring in 23 day(s) on June 20, 2025. This event was a transfer of 137 contract(s) at a $195.00 strike. The total cost received by the writing party (or parties) was $25.8K, with a price of $189.0 per contract. There were 5038 open contracts at this strike prior to today, and today 319 contract(s) were bought and sold. 
• Regarding COR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), we observe a put option sweep with neutral sentiment. It expires in 23 day(s) on June 20, 2025. Parties traded 135 contract(s) at a $280.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $36.4K, with a price of $270.0 per contract. There were 762 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

AMGN

GILD

MRNA

REGN

VEEV

10 Health Care Stocks Whale Activity In Today's Session

Benzinga examined the prospects for<a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener"> many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
U.S. markets experienced heightened volatility this week as President Donald Trump intensified trade tensions by threatening a 25% tariff on foreign-made Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) products and announcing a 50% tariff on European Union imports starting June 1. These announcements led to a decline in major indices, with the S&amp;P 500 falling 0.7%, the Dow Jones dropping 0.6%, and the Nasdaq decreasing by 1%. Apple shares were particularly affected, losing 3% in value.
Investor concerns over the U.S. fiscal outlook grew as the 30-year Treasury yield briefly surpassed 5.15%, reflecting apprehensions about rising deficits and debt sustainability. A weak 20-year Treasury auction further exacerbated these fears, indicating diminished demand for long-term U.S. debt.
Looking ahead, market participants are closely monitoring upcoming U.S.-China trade negotiations and potential adjustments to existing tariffs. The Federal Reserve's stance on interest rates remains a focal point, especially as real borrowing costs rise, tightening broader financial conditions. Additionally, corporate earnings reports and economic indicators will continue to influence market dynamics in the coming weeks.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls
<a href="https://www.benzinga.com/trading-ideas/technicals/25/05/45544614/google-could-smart-glasses-smart-speech-spark-the-stocks-next-big-leap">"Google: Could smart glasses, speech spark the stock's next big leap?"</a>, by Surbhi Jain, reports that Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) is gaining investor attention as its partnership with Warby Parker to develop AI-powered smart glasses and advancements in speech recognition technology signal a potential new growth narrative beyond search.
<a href="https://www.benzinga.com/government/regulations/25/05/45574763/goldman-sachs-defense-stock-golden-dome">"Goldman Sachs: Golden Dome is big win for this defense stock"</a>, by Piero Cingari, reports that Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) analyst Noah Poponak reiterated a Buy rating on L3Harris Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>), highlighting its potential to secure billions in contracts from the Trump administration's $175 billion "Golden Dome" missile defense initiative.
<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45531583/amd-nvidia-shares-jump-after-musk-highlights-xais-gpu-needs-we-expect-to-still-buy-a-lot">"AMD, Nvidia shares jump after Musk highlights xAI's GPU needs: ‘We expect to still buy a lot'"</a>, by Adam Eckert, reports that Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares rose after Elon Musk stated that Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and xAI plan to purchase "a lot" of GPUs from both companies to support AI initiatives like robotaxis and the Optimus robot.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45541780/d-wave-quantum-stock-extends-rally-as-momentum-builds-following-launch-of-new-quantum-system">D-Wave Quantum Stock Extends Rally As Momentum Builds Following Launch Of New Quantum System</a>
<a href="https://www.benzinga.com/25/05/45517783/magnificent-7-stun-the-street-with-the-best-earnings-beat-since-2021">Magnificent 7 Stun The Street With Best Earnings Beat Since 2021</a>
<a href="https://www.benzinga.com/25/05/45540768/medtronic-beats-q4-forecasts-hikes-dividend-plans-diabetes-spinoff">Medtronic Beats Q4 Forecasts, Hikes Dividend, Plans Diabetes Spinoff</a>

The Bears
<a href="https://www.benzinga.com/news/legal/25/05/45568107/solar-energy-stocks-drop-as-house-approves-major-rollback-of-climate-incentives">"Solar energy stocks drop as House approves major rollback of climate incentives"</a>, by Erica Kollmann, reports that Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares fell after the House passed President Trump's "One Big, Beautiful Bill," which rolls back key climate incentives, leaving the solar industry facing uncertainty as the bill moves to the Senate.
<a href="https://www.benzinga.com/25/05/45540759/target-stock-slips-as-q1-earnings-miss-estimates-fy2025-outlook-cut-amid-slowing-sales">"Target stock slips as Q1 earnings miss estimates, FY2025 outlook cut amid slowing sales"</a>, by Nabaparna Bhattacharya, reports that Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) shares fell after the company missed Q1 earnings expectations and lowered its FY2025 outlook, citing a 3.8% drop in comparable sales driven by tariffs, weakened consumer sentiment, and backlash from scaling back diversity, equity, and inclusion initiatives.
<a href="https://www.benzinga.com/news/rumors/25/05/45555558/wolfspeed-stock-plunges-59-on-bankruptcy-fears-options-traders-cash-in">"Wolfspeed stock plunges 59% on bankruptcy fears: Options traders cash in"</a>, by Erica Kollmann, reports that Wolfspeed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares plummeted 59% to $1.28 after reports emerged that the company is preparing to file for Chapter 11 bankruptcy, with options traders profiting from heavy put activity ahead of the news.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/government/regulations/25/05/45554854/health-care-stocks-like-unitedhealth-cvs-tank-on-wednesday-heres-why">Health Care Stocks Like UnitedHealth, CVS Tank On Wednesday: Here's Why</a>
<a href="https://www.benzinga.com/25/05/45567780/hims-hers-health-stock-is-tumbling-thursday-whats-happening">Hims &amp; Hers Health Stock Is Tumbling Thursday: What's Happening?</a>
<a href="https://www.benzinga.com/markets/equities/25/05/45532892/legendary-investor-jeremy-grantham-warns-of-50-stock-market-crash">Legendary Investor Jeremy Grantham Warns Of 50% Stock Market Crash</a>

Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

AAPL

GOOGL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

NVDA

QBTS

TSLA

WOLF

Benzinga Bulls And Bears: Alphabet, L3Harris, Target — And Latest Tariff News Roils Markets

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/23/25</td>
<td>$300.00</td>
<td>$25.7K</td>
<td>6.4K</td>
<td>7.0K</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$76.00</td>
<td>$244.0K</td>
<td>10</td>
<td>4.0K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$1000.00</td>
<td>$25.6K</td>
<td>361</td>
<td>274</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$400.00</td>
<td>$52.8K</td>
<td>46</td>
<td>15</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$450.00</td>
<td>$30.4K</td>
<td>93</td>
<td>6</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be neutral, expiring in 1 day(s) on May 23, 2025. This event was a transfer of 60 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $25.7K, with a price of $429.0 per contract. There were 6422 open contracts at this strike prior to today, and today 7074 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a put option trade that happens to be bullish, expiring in 36 day(s) on June 27, 2025. This event was a transfer of 4000 contract(s) at a $76.00 strike. The total cost received by the writing party (or parties) was $244.0K, with a price of $61.0 per contract. There were 10 open contracts at this strike prior to today, and today 4000 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bearish sentiment. It expires in 85 day(s) on August 15, 2025. Parties traded 54 contract(s) at a $1000.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.6K, with a price of $475.0 per contract. There were 361 open contracts at this strike prior to today, and today 274 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bullish, expiring in 392 day(s) on June 18, 2026. This event was a transfer of 12 contract(s) at a $400.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $52.8K, with a price of $4400.0 per contract. There were 46 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a put option trade that happens to be neutral, expiring in 392 day(s) on June 18, 2026. This event was a transfer of 5 contract(s) at a $450.00 strike. The total cost received by the writing party (or parties) was $30.4K, with a price of $6080.0 per contract. There were 93 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRTX

5 Health Care Stocks Whale Activity In Today's Session

Mizuho analyst Anthony Petrone maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform and lowers the price target from $100 to $98.

Price Target

Mizuho Maintains Outperform on Medtronic, Lowers Price Target to $98

RBC Capital analyst Shagun Singh maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform and lowers the price target from $105 to $101.

RBC Capital Maintains Outperform on Medtronic, Lowers Price Target to $101

Baird analyst David Rescott maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Neutral and lowers the price target from $94 to $92.

Baird Maintains Neutral on Medtronic, Lowers Price Target to $92

U.S. equities trading was mixed on Wednesday, with major indices showing limited movement by midday as investors remained cautious amid renewed concerns over fiscal policy, which pressured Treasury <a href="https://www.benzinga.com/government/regulations/25/05/45540541/5-treasury-yields-are-back-and-so-are-painful-mortgage-rates">bonds and the dollar.</a>
The S&amp;P 500 hovered near 5,930, little changed on the day, while the Dow Jones Industrial Average slipped 0.7% amid weakness in blue-chip stocks. In contrast, the Nasdaq 100 advanced 0.5%, led by a 4.6% rally in Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), which extended gains following its annual I/O developer conference.
Google unveiled a series of AI initiatives, highlighting that its Gemini assistant now boasts over 400 million monthly active users and delivers AI Overviews to more than 1.5 billion people. The company also touted Gemini 2.5 Pro's <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45548615/alphabet-well-positioned-for-google-search-dominance-analyst-says-can-navigate-the-shift-to-ai-search">performance leadership in industry benchmark</a>s.
Bond markets faced renewed selling pressure, with the 30-year Treasury yield surging to 5.02% — the highest in nearly two months — as traders digested the potential fiscal implications of President Donald Trump&#8216;s proposed "One Big Beautiful Bill," which economists say could further worsen the U.S. deficit outlook.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) stole the spotlight, surging past its previous record to hit an intraday high of $109,500, buoyed by news that JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) will allow clients to buy Bitcoin, though without offering custody services.
In commodities, oil prices eased 0.6% to $61.50 per barrel after an overnight spike triggered by unconfirmed reports of an Israeli strike on Iranian nuclear facilities. Gold rose 0.5% to $3,310 per ounce, marking its highest level since May 11.
<h1 class="wp-block-heading">Wednesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,474.58</td>
<td>0.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,936.07</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,379.01</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,084.27</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:40 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.2% down to $591.96.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fell 0.7% to $423.84.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.4% to $522.58.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) sunk 1% to $207.08.</li>
<li>The&nbsp;Communication Services&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) outperformed, up 0.6%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 1.2%.</li>
</ul>
<h1 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h1>
<ul class="wp-block-list">
<li>Keysight Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) rose 3.3% in reaction to earnings. </li>
<li>Other stocks reacting to earnings included TJX Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>), down 2.33; Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>), down 1.23%; Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), down 0.93%; Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>), down 4.12%; VF Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>), down 12.04%, FLEX LNG Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLNG#NYSE">FLNG</a>), down 7.27%.</li>
<li>Stocks slated to report earnings after the close include Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>), Zoom Video Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>), Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) and Domo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>).</li>
</ul>
Read Now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45548192/tesla-enters-its-most-bullish-window-this-seasonal-trade-delivered-24-average-gain-over-10-years">Tesla Enters Its Most Bullish Window: This Seasonal Trade Delivered 24% Average Gain Over 10 Years</a> Photo Courtesy: Antonio Gravante via Shutterstock </li>
</ul>

Equities

Large Cap

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

DOMO

FLNG

GOOG

KEYS

SNOW

URBN

Select Sector SPDR-Consumer Discretionary

Wall Street Stalls As Yields Rise, Bitcoin Breaks Records Above $109,000: What's Driving Markets Wednesday?

Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported fourth-quarter 2025 sales of $8.93 billion, beating the <a href="https://www.benzinga.com/pressreleases/25/05/n45538067/medtronic-reports-strong-finish-to-its-fiscal-year-with-its-fourth-quarter-financial-results-annou" target="_blank" rel="noreferrer noopener">consensus of $8.82 billion</a>.
The medical device maker reported:
<ul class="wp-block-list">
<li>Adjusted EPS of $1.62, beating the consensus of $1.58.</li>
<li>A year-over-year revenue increase of 3.9% <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">and 5.4% Y/Y organically</a>.</li>
<li>Cardiovascular segment revenue reaching $3.34 billion, up 6.6% year over year as reported, and increased 7.8% Y/Y organically.</li>
<li>An increase in low-double-digit in CRHF, high-single-digit in SH&amp;A, and low-single-digit in CPV (all on an organic basis).</li>
<li>Neuroscience revenues of $2.62 billion rose 2.9% Y/Y as reported. They rose 3.7% Y/Y organically, aided by an increase in low-double-digit in Neuromodulation and mid-single-digit in CST, all on an organic basis.</li>
<li>Medical Surgical&nbsp;revenue of&nbsp;$2.21 billion increased by&nbsp;0.6% Y/Y&nbsp;as reported and by&nbsp;2.0%&nbsp;Y/Y organically, with a low-single-digit organic growth in both SE and ACM segments.</li>
<li>Diabetes revenue of&nbsp;$728 million increased by&nbsp;10.4% Y/Y, as reported, and by&nbsp;12.0%&nbsp;Y/Y organically.</li>
</ul>
Dividend Increase: Effective May 20, the company&#8217;s board approved an increase in cash dividend per share by 1.4% to 71 cents for the first quarter of fiscal year 2026
The dividend is payable on&nbsp;July 11, 2025, to shareholders of record as of&nbsp;June 27, 2025.
Guidance:&nbsp;Medtronic expects its fiscal year 2026 organic <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">revenue&nbsp;growth&nbsp;guidance&nbsp;of&nbsp;5%</a>.
If recent foreign currency exchange rates hold, FY26 revenue growth would be around&nbsp;&nbsp;4.8% to 5.1% on a reported basis.
Medtronic expects 2025 adjusted EPS of&nbsp;$5.50-$5.60&nbsp;versus consensus of&nbsp;$5.83.
Diabetes Business Separation: Medtronic disclosed its intention to separate its Diabetes <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45538032/medtronic-announces-intent-to-separate-diabetes-business" rel="noreferrer noopener">business into a new standalone company</a>.
This move aims to create a more focused entity with a streamlined portfolio concentrated on high-margin growth markets.
The separation, expected within 18 months, will occur through capital markets transactions, with an initial public offering (IPO) followed by a split-off as the preferred method.
Upon separation, Medtronic anticipates an immediate improvement of approximately 50 basis points in adjusted gross margin, 100 basis points in adjusted operating margins, and an immediate accretion to adjusted EPS.
The separation is also expected to allow Medtronic to retire outstanding shares without impacting cash, leading to further EPS accretion and a reduced dividend liability.
Investors can gain exposure to the stock via Madison ETFs Trust Madison Covered Call ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVRD#NYSE">CVRD</a>) and Absolute Select Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEQ#NYSE">ABEQ</a>).
Price Action:&nbsp;MDT stock is down 0.14% at $86.25 premarket at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/03/44451449/china-courts-apple-pfizer-eli-lilly-amid-us-pressure-vice-premier-says-beijing-will-continue-to-improve-the-business-environment" target="_blank" rel="noreferrer noopener">China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing &#8216;Will Continue To Improve The Business Environment&#8217;</a></li>
</ul>
Image: Shutterstock

Guidance

Dividends

ABEQ

CVRD

Medtronic Beats Q4 Forecasts, Hikes Dividend, Plans Diabetes Spinoff

Guidance The company today issued its fiscal year 2026 (FY26) revenue growth and EPS guidance.
The company is guiding to FY26 organic revenue growth of approximately 5%. The organic revenue growth guidance excludes the impact of foreign currency exchange and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY26 revenue growth on a reported basis would be in the range of 4.8% to 5.1%.
Excluding the potential impacts from increased tariffs, Medtronic expects FY26 diluted non-GAAP EPS growth to be approximately 4%. This includes an expectation for non-GAAP operating profit to grow faster than organic revenue, partially offset by increased interest and tax expense. Including a potential impact from tariffs as detailed in the company's earnings presentation, Medtronic is guiding FY26 diluted non-GAAP EPS in the range of $5.50 to $5.60. The lower end of the EPS range assumes that the bilateral US/China tariffs resume at the higher rates following the 90 day pause, while the higher end of the EPS range assumes that the bilateral US/China tariffs currently in effect during the pause remain in place through fiscal year 2026.
"Our fiscal 2026 guidance reflects increasing revenue growth contribution from our key growth drivers, and increased investment to support their growth, leading to leveraged operating profit growth pre-tariffs. In addition, the team has rallied to identify opportunities to offset a large portion of tariffs, and we have high confidence in our ability to execute additional mitigation efforts," said Thierry Piéton, Medtronic chief financial officer, who joined the company on March 3, 2025. "This is an exciting time to join Medtronic. I am energized by the opportunities for durable growth and value creation ahead of us."

Medtronic Sees FY2026 Adj EPS $5.50-$5.60 Vs $5.83 Est., Sees 5% Organic Revenue Growth

Dividend Increase The company today announced that effective May 20, 2025, the Medtronic board of directors approved an increase in Medtronic's cash dividend for the first quarter of fiscal year 2026, raising the quarterly amount to $0.71 per ordinary share. This would translate into an annual amount of $2.84 per ordinary share. Today's announcement marks the 48th consecutive year of an increase in the dividend payment. The dividend is payable on July 11, 2025, to shareholders of record at the close of business on June 27, 2025.

Medtronic Boosts Quarterly Dividend By 1.4% To $0.71, Payable July 11

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported quarterly earnings of $1.62 per share which beat the analyst consensus estimate of $1.58 by 2.53 percent. This is a 10.96 percent increase over earnings of $1.46 per share from the same period last year. The company reported quarterly sales of $8.93 billion which beat the analyst consensus estimate of $8.82 billion by 1.17 percent. This is a 3.94 percent increase over sales of $8.59 billion the same period last year.

Earnings Beats

Medtronic Q4 Adj. EPS $1.62 Beats $1.58 Estimate, Sales $8.93B Beat $8.82B Estimate

Medtronic Announced Its Intent To Separate Its Diabetes Business Into A New Standalone Company

<h3>Companies Reporting Before The Bell</h3>
• MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is likely to report quarterly loss at $0.66 per share on revenue of $5.20 million. 
• Canada Goose Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#NYSE">GOOS</a>) is expected to report quarterly earnings at $0.16 per share on revenue of $262.86 million. 
• Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is projected to report quarterly loss at $0.04 per share on revenue of $18.20 million. 
• iQIYI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $973.69 million. 
• TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) is estimated to report quarterly earnings at $0.91 per share on revenue of $13.03 billion. 
• Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) is expected to report quarterly earnings at $1.58 per share on revenue of $8.83 billion. 
• Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is likely to report quarterly earnings at $1.65 per share on revenue of $24.35 billion. 
• Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) is likely to report quarterly earnings at $2.88 per share on revenue of $20.97 billion. 
• Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) is estimated to report quarterly earnings at $1.34 per share on revenue of $4.30 billion. 
• Full Truck Alliance Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YMM#NYSE">YMM</a>) is estimated to report quarterly earnings at $0.16 per share on revenue of $366.75 million. 
• CMB.Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMBT#NYSE">CMBT</a>) is projected to report quarterly earnings at $0.28 per share on revenue of $224.00 million. 
• Golden Ocean Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGL#NASDAQ">GOGL</a>) is projected to report quarterly loss at $0.15 per share on revenue of $106.48 million. 
• Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) is projected to report quarterly earnings at $1.66 per share on revenue of $471.83 million. 
• Flex LNG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLNG#NYSE">FLNG</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $88.17 million. 
• Cool Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLCO#NYSE">CLCO</a>) is estimated to report earnings for its first quarter. 
• Dycom Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DY#NYSE">DY</a>) is projected to report quarterly earnings at $1.62 per share on revenue of $1.19 billion. 
• Super Hi International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDL#NASDAQ">HDL</a>) is likely to report earnings for its first quarter. 
• Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) is projected to report quarterly loss at $0.73 per share on revenue of $4.00 million. 
• WeRide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) is likely to report earnings for its first quarter. 
• Baozun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZUN#NASDAQ">BZUN</a>) is projected to report earnings for its first quarter. 
• XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) is likely to report earnings for its first quarter. 
• VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $2.17 billion. 
• Weibo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WB#NASDAQ">WB</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $394.21 million. 
<h3>Companies Reporting After The Bell</h3>
• LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) is projected to report quarterly earnings at $0.28 per share on revenue of $185.41 million. 
• Banco BBVA Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAR#NYSE">BBAR</a>) is projected to report quarterly earnings at $0.47 per share on revenue of $708.59 million. 
• Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is projected to report quarterly earnings at $1.31 per share on revenue of $1.17 billion. 
• Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) is expected to report quarterly earnings at $0.82 per share on revenue of $1.29 billion. 
• American Superconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSC#NASDAQ">AMSC</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $60.27 million. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is likely to report earnings for its first quarter. 
• Domo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>) is likely to report quarterly loss at $0.19 per share on revenue of $77.75 million. 
• ClearSign Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIR#NASDAQ">CLIR</a>) is projected to report earnings for its first quarter. 
• Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $1.01 billion. 
• EnerSys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENS#NYSE">ENS</a>) is projected to report quarterly earnings at $2.55 per share on revenue of $1.02 billion. 
• Borr Drilling (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BORR#NYSE">BORR</a>) is likely to report quarterly loss at $0.03 per share on revenue of $231.17 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMSC

BBAR

BORR

BZUN

CLCO

CLIR

CMBT

EVGN

GOGL

GOOS

MDWD

RAMP

XPEV

Earnings Scheduled For May 21, 2025

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-05-21. Here's what investors need to know before the announcement.
Analysts estimate that Medtronic will report an earnings per share (EPS) of $1.58. 
Medtronic bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.03 in the last quarter, leading to a 1.08% increase in the share price on the following day.
Here's a look at Medtronic's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.36</td>
<td>1.25</td>
<td>1.20</td>
<td>1.45</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.39</td>
<td>1.26</td>
<td>1.23</td>
<td>1.46</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>3.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747749672_0.png" alt="eps graph" />
<h3>Performance of Medtronic Shares</h3>
Shares of Medtronic were trading at $86.97 as of May 19. Over the last 52-week period, shares are up 1.1%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Opinions on Medtronic</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Medtronic.
Analysts have given Medtronic a total of 5 ratings, with the consensus rating being Neutral. The average one-year price target is $97.6, indicating a potential 12.22% upside.
<h3>Peer Ratings Comparison</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Stryker, Boston Scientific and Becton Dickinson, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Stryker, with an average 1-year price target of $427.6, suggesting a potential 391.66% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Boston Scientific, with an average 1-year price target of $117.78, suggesting a potential 35.43% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Becton Dickinson, with an average 1-year price target of $225.2, suggesting a potential 158.94% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary provides a snapshot of key metrics for Stryker, Boston Scientific and Becton Dickinson, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medtronic</td>
<td>Neutral</td>
<td>2.51%</td>
<td>$5.51B</td>
<td>2.64%</td>
</tr>
<tr>
<td>Stryker</td>
<td>Buy</td>
<td>11.88%</td>
<td>$3.74B</td>
<td>3.15%</td>
</tr>
<tr>
<td>Boston Scientific</td>
<td>Outperform</td>
<td>20.93%</td>
<td>$3.21B</td>
<td>3.06%</td>
</tr>
<tr>
<td>Becton Dickinson</td>
<td>Outperform</td>
<td>4.50%</td>
<td>$2.26B</td>
<td>1.22%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Medtronic ranks second in consensus rating among its peers. It ranks last in revenue growth. It ranks first in gross profit. It ranks last in return on equity.
<h3>All You Need to Know About Medtronic</h3>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
<h3>Financial Insights: Medtronic</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Medtronic showcased positive performance, achieving a revenue growth rate of 2.51% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medtronic's net margin is impressive, surpassing industry averages. With a net margin of 15.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.64%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Medtronic's ROA excels beyond industry benchmarks, reaching 1.44%. This signifies efficient management of assets and strong financial health.
Debt Management: Medtronic's debt-to-equity ratio is below the industry average at 0.54, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/MDT/earnings">To track all earnings releases for Medtronic visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Medtronic's Earnings

5 analysts have shared their evaluations of Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Medtronic and provided 12-month price targets. The average target is $97.6, accompanied by a high estimate of $107.00 and a low estimate of $90.00. This upward trend is apparent, with the current average reflecting a 4.95% increase from the previous average price target of $93.00.
<img src="https://www.benzinga.com/files/images/story/2025/1747656061_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Medtronic's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$90.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$91.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Medtronic. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Medtronic's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Medtronic's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Medtronic analyst ratings.</a>
<h2>Get to Know Medtronic Better</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
<h3>Medtronic: A Financial Overview</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Medtronic's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.51% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Medtronic's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Medtronic's ROE stands out, surpassing industry averages. With an impressive ROE of 2.64%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.44%, the company showcases effective utilization of assets.
Debt Management: Medtronic's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.54.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Medtronic: What You Need To Know

Press Releases

Medtronic receives FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure™ lead and announces investigational clinical study results

Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system

Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients

New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Medtronic announces intent to separate Diabetes business

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Small Cap

AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names

AVAI

BFLY

OBIO

ORCL

RXRX

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

TransMedics Group

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Mizuho

RBC Capital

Baird

Truist Securities

Citigroup

Screenshot 2024-10-03 at 5.30.47 PM

Health Care

DXCM

GCTK

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Comments

Medtronic

Noticias

Últimas noticias sobre Medtronic (NYSE:MDT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL